Experts hail highly successful trial of Lilly's cholesterol-busting drug lepodisiran
Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...
pharmaphorum4d
ACC25: Positive results with Lilly's Lp(a)-lowering drug
Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...
BioPharma Dive4d
Lilly study data reinforce potential of new kind of heart drug
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...
Fierce Biotech4d
Lilly links lepodisiran to durably lower lipoprotein in phase 2, providing edge over Amgen and Novartis
Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, ...
Eli Lilly Phase 2 Lipoprotein(a) Study Hits Primary Endpoint
Eli Lilly on Sunday said the Phase 2 study of lepodisiran, designed to lower the production of lipoprotein (a), or lp (a), met its primary endpoint, reducing lp (a) levels by an average of 93.9% over ...
Healio5d
Lepodisiran lowers Lp(a) substantially with infrequent administration
CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...
Explore more
BioSpace4d
Lilly’s RNA Silencer Lowers Key Cardiovascular Biomarker by Almost 94%
BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...
PharmiWeb4d
Lilly's lepodisiran reduced levels of genetically…
Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) ...